title: [The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].
abstract: OBJECTIVE
  To investigate the protein expression of ERCC1 (excision repair cross complementation group 1) and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma (EOC), and to explore the relationship among ERCC1 expression, survivin expression, the major clinicopathological characteristics as well as platinum sensitivity.
  
  
  METHODS
  Expression of ERCC1 and survivin were detected in 64 EOC tissues by immunohistochemical method.
  
  
  RESULTS
  No significant differences were found in patients' age, FIGO stage, pathological type, histological grade, pelvic lymph node and/or vessel infiltration, in all of three pairs of comparison. They were platinum-sensitive group vs. platinum-resistant group, ERCC1-positive group vs. ERCC1-negative group and surviving-positive group vs. survivn-negative group (all P > 0.05). The positive rate of ERCC1 expression (67.85%, 19/28) in platinum-resistant patients' tissues was significantly higher than that in platinum-sensitive patients' tissues (25.00%, 9/36) (P = 0.001). While the positive rate of survivin in platinum-resistant patients' tissues (78.57%, 22/28) was slightly higher than that of in platinum-sensitive patients' tissues (75.00%, 29/36), however without significant (P = 0.74). No evidence was found that the expression of ERCC1 correlate with the expression of survivin (r(s) = 0.12, P = 0.36) too. The proportion of platinum-resistant in patients with coexpression of ERCC1 and surviving (65.22%, 15/23) was insignificantly lower than that of in patients with single expression of ERCC1 (80.00%, 4/5) (P = 0.91).
  
  
  CONCLUSIONS
  Expression of ERCC1 in EOC patients' tumor tissue could be a predictive indicator for their platinum susceptibility and it might be helpful for prevention and reverse of platinum resistance in clinical practice. The expression of survivin seems of no definite value in prediction of platinum susceptibility.
authors.affiliation: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Xie
authors.forename: Ru-tie
authors.initials: RT
authors.lastname: Yin
authors.forename: Yu-ling
authors.initials: YL
authors.lastname: Li
authors.forename: De-ying
authors.initials: DY
authors.lastname: Kang
authors.forename: Lian
authors.initials: L
authors.lastname: Xu
authors.forename: Kai-xuan
authors.initials: KX
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000077022:Survivin; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D004268:DNA-Binding Proteins; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin